Patients with cardiovascular disease diagnosed with novel coronavirus (COVID-19) are urged to continue taking their angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) medications as prescribed.
Initiation of antihypertensive or statin therapy was found to be associated with both positive and negative lifestyle changes.
On March 6, 2020, the American College of Cardiology issued COVID-19 clinical guidance for the cardiovascular care team.
Electrocardiography is a valuable tool to assess left ventricular hypertrophy, which has been associated with the development of major cardiovascular events.
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Medication doses do not need to be reduced in response to symptomless orthostatic hypotension, authors say
Pulmonary hypertension can be a severe and potentially debilitating complication in patients with chronic left-sided heart failure.
Greater variability in systolic blood pressure measurements across visits in young adults may be associated with elevated risks for cardiovascular disease and all-cause mortality in midlife.
Treatment with amlodipine was found to be more effective at reducing the long-term risk for gout compared with treatment with lisinopril or chlorthalidone in older adults with hypertension.
Isolated diastolic hypertension, as defined in the 2017 ACC/AHA guideline was found to be more prevalent compared with IDH defined according to a 2003 recommendation.